Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 7/20 | 0.55 |
| ▸ | DRD3 | P35462 | 5/20 | 0.55 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.51 |
| ▸ | HTR1A | P08908 | 2/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.49 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | DRD4 | P21917 | 4/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9365199 | 0.88 | DRD2 (0.66) | DRD2DRD3CYP19A1CHRM2CHRM1 | |
| Hydrochloric Acid SCHEMBL9688990 | 0.86 | DRD2 (0.64) | DRD2DRD3CYP19A1CHRM2CHRM1 | |
| SCHEMBL339482 | 0.84 | DRD2 (0.54) | DRD2DRD3CYP19A1HTR1ACHRM2 | |
| SCHEMBL8970384 | 0.80 | CHRM2 (0.60) | DRD2DRD3CYP19A1HTR1ACHRM2 | |
| SCHEMBL338365 | 0.80 | CYP19A1 (0.47) | DRD2DRD3CYP19A1HTR1ACHRM2 | |
| Hydrochloric Acid SCHEMBL9688982 | 0.79 | CHRM2 (0.59) | DRD2DRD3CYP19A1HTR1ACHRM2 | |
| SCHEMBL338363 | 0.77 | DRD2 (0.77) | DRD2DRD3HTR1ADRD4 | |
| SCHEMBL3318321 | 0.77 | HTR1A (0.81) | DRD2DRD3HTR1ACHRM2CHRM1 | |
| SCHEMBL2700779 | 0.75 | DRD2 (0.59) | DRD2DRD3CYP19A1CHRM2CHRM1 | |
| SCHEMBL338704 | 0.74 | HTR1A (0.46) | DRD2CYP19A1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097641-B2 | Heterocyclyl substituted tetrahydronaphthalene derivatives as 5-HT7 receptor ligands | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-01-17 | — | — | US | claimed |
| US-20100035936-A1 | HETEROCYCLYL SUBSTITUTED TETRAHYDRONAPHTHALENE DERIVATIVES AS 5-HT7 RECEPTOR LIGANDS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-02-11 | — | — | US | claimed |
| EP-2114893-A1 | HETEROCYCLYL SUBSTITUTED TETRAHYDRONAPHTHALENE DERIVATIVES AS 5-HT7 RECEPTOR LIGANDS | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-11-11 | — | — | EP | claimed |
| WO-2008095689-A1 | HETEROCYCLYL SUBSTITUTED TETRAHYDRONAPHTHALENE DERIVATIVES AS 5-HT7 RECEPTOR LIGANDS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-08-14 | — | — | WO | claimed |
| US-8097641-B2 | Heterocyclyl substituted tetrahydronaphthalene derivatives as 5-HT7 receptor ligands | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-01-17 | — | — | US | disclosed |
| US-20100035936-A1 | HETEROCYCLYL SUBSTITUTED TETRAHYDRONAPHTHALENE DERIVATIVES AS 5-HT7 RECEPTOR LIGANDS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-02-11 | — | — | US | disclosed |
| EP-2114893-A1 | HETEROCYCLYL SUBSTITUTED TETRAHYDRONAPHTHALENE DERIVATIVES AS 5-HT7 RECEPTOR LIGANDS | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008095689-A1 | HETEROCYCLYL SUBSTITUTED TETRAHYDRONAPHTHALENE DERIVATIVES AS 5-HT7 RECEPTOR LIGANDS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035936-A1 | HETEROCYCLYL SUBSTITUTED TETRAHYDRONAPHTHALENE DERIVATIVES AS 5-HT7 RECEPTOR LIGANDS | HTR7, HTR2C, HTR6 | DRD2 264/4885DRD3 370/4885CYP19A1 480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.